Ginsenoside Rg1 ameliorates motor function in an animal model of Parkinson's disease

Pharmacology

Volumn 96, Issue 1-2, 2015, Pages 25-31

  Jiang, Wenda ^a   Wang, Zhejian ^b   Jiang, Yiyang ^a   Lu, Meili ^a   Li, Xin ^c  

^a JINZHOU MEDICAL UNIVERSITY   (China)

^b DALIAN MEDICAL UNIVERSITY   (China)

^c Jinzhou Central Hospital   (China)

Author keywords

Dopaminergic neuron; Ginsenoside Rg1; MPTP; Parkinson's disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; GINSENOSIDE RG 1; GINSENOSIDE; TYROSINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN TISSUE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; LOCOMOTION; MOTOR PERFORMANCE; MOUSE; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; POLE TEST; PRIORITY JOURNAL; RAT; ROTAROD TEST; ANIMAL; CHEMICALLY INDUCED; DISEASE MODEL; DRUG EFFECTS; METABOLISM; PARKINSON DISEASE, SECONDARY; SUBSTANTIA NIGRA;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DOPAMINERGIC NEURONS; GINSENOSIDES; MICE; MOTOR SKILLS; PARKINSON DISEASE, SECONDARY; SUBSTANTIA NIGRA; TYROSINE 3-MONOOXYGENASE;

EID: 84930922545     PISSN: 00317012     EISSN: 14230313     Source Type: Journal    
DOI: 10.1159/000431100     Document Type: Article

References (28)

1. Garcia Ruiz PJ, Catalán MJ, Fernández Carril JM: Initial motor symptoms of Parkinson disease. Neurologist 2011; 17(6 suppl 1): S18-S20.
2. Hallett M: Parkinson revisited: pathophysiology of motor signs. Adv Neurol 2003; 91: 19-28.
3. Larsen JP, Beiske AG, Bekkelund SI, Dietrichs E, Tysnes OB, Vilming ST, Aasly JO: [Motor symptoms in Parkinson disease]. Tidsskr Nor Laegeforen 2008; 128: 2068-2071.
4. Stefanis L: Synuclein in Parkinson's disease. Cold Spring Harb Perspect Med 2012; 2: a009399.
5. Cookson MR: Alpha-synuclein and neuronal cell death. Mol Neurodegener 2009; 4: 9.
6. Fountaine TM, Wade-Martins R: RNA interference-mediated knockdown of alpha-synuclein protects human dopaminergic neuroblastoma cells from MPP(+) toxicity and reduces dopamine transport. J Neurosci Res 2007; 85: 351-363.
7. Hayashita-Kinoh H, Yamada M, Yokota T, Mizuno Y, Mochizuki H: Down-regulation of alpha-synuclein expression can rescue dopaminergic cells from cell death in the substantia nigra of Parkinson's disease rat model. Biochem Biophys Res Commun 2006; 341: 1088-1095.
8. Klivenyi P, Siwek D, Gardian G, Yang L, Starkov A, Cleren C, Ferrante RJ, Kowall NW, Abeliovich A, Beal MF: Mice lacking alphasynuclein are resistant to mitochondrial toxins. Neurobiol Dis 2006; 21: 541-548.
9. McCormack AL, Mak SK, Henderson JM, Bumcrot D, Farrer MJ, Di Monte DA: Alphasynuclein suppression by targeted small interfering RNA in the primate substantia nigra. PLoS One 2010; 5:e12122.
10. Radad K, Gille G, Moldzio R, Saito H, Rausch WD: Ginsenosides Rb1 and Rg1 effects on mesencephalic dopaminergic cells stressed with glutamate. Brain Res 2004; 1021: 41-53.
11. Chen XC, Fang F, Zhu YG, Chen LM, Zhou YC, Chen Y: Protective effect of ginsenoside Rg1 on MPP+-induced apoptosis in shsy5y cells. J Neural Transm 2003; 110: 835-845.
12. Radad K, Gille G, Moldzio R, Saito H, Ishige K, Rausch WD: Ginsenosides Rb1 and Rg1 effects on survival and neurite growth of MPP+-affected mesencephalic dopaminergic cells. J Neural Transm 2004; 111: 37-45.
13. Leung KW, Yung KK, Mak NK, Chan YS, Fan TP, Wong RN: Neuroprotective effects of ginsenoside-Rg1 in primary nigral neurons against rotenone toxicity. Neuropharmacology 2007; 52: 827-835.
14. Chen XC, Chen Y, Zhu YG, Fang F, Chen LM: Protective effect of ginsenoside Rg1 against MPTP-induced apoptosis in mouse substantia nigra neurons. Acta Pharmacol Sin 2002; 23: 829-834.
15. Fleming SM, Salcedo J, Fernagut PO, Rockenstein E, Masliah E, Levine MS, Chesselet MF: Early and progressive sensorimotor anomalies in mice overexpressing wild-type human alpha-synuclein. J Neurosci 2004; 24: 9434-9440.
16. Sedelis M, Hofele K, Auburger GW, Morgan S, Huston JP, Schwarting RK: MPTP susceptibility in the mouse: behavioral, neurochemical, and histological analysis of gender and strain differences. Behav Genet 2000; 30: 171-182.
17. Sedelis M, Schwarting RK, Huston JP: Behavioral phenotyping of the MPTP mouse model of Parkinson's disease. Behav Brain Res 2001; 125: 109-125.
18. Jackson-Lewis V, Przedborski S: Protocol for the MPTP mouse model of Parkinson's disease. Nat Protoc 2007; 2: 141-151.
19. Chen PC, Vargas MR, Pani AK, Smeyne RJ, Johnson DA, Kan YW, Johnson JA: Nrf2-mediated neuroprotection in the MPTP mouse model of Parkinson's disease: critical role for the astrocyte. Proc Natl Acad Sci U S A 2009; 106: 2933-2938.
20. Goldberg NR, Haack AK, Lim NS, Janson OK, Meshul CK: Dopaminergic and behavioral correlates of progressive lesioning of the nigrostriatal pathway with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neuroscience 2011; 180: 256-271.
21. Hefti F, Melamed E, Wurtman RJ: Partial lesions of the dopaminergic nigrostriatal system in rat brain: biochemical characterization. Brain Res 1980; 195: 123-137.
22. Jakowec MW, Nixon K, Hogg E, McNeill T, Petzinger GM: Tyrosine hydroxylase and dopamine transporter expression following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridineinduced neurodegeneration of the mouse nigrostriatal pathway. J Neurosci Res 2004; 76: 539-550.
23. Trojanowski JQ, Lee VM: Parkinson's disease and related alpha-synucleinopathies are brain amyloidoses. Ann N Y Acad Sci 2003; 991: 107-110.
24. Ardah MT, Paleologou KE, Lv G, Menon SA, Abul Khair SB, Lu JH, Safieh-Garabedian B, Al-Hayani AA, Eliezer D, Li M, El-Agnaf OM: Ginsenoside Rb1 inhibits fibrillation and toxicity of alpha-synuclein and disaggregates preformed fibrils. Neurobiol Dis 2015; 74: 89-101.
25. Hockenbery DM, Oltvai ZN, Yin XM, Milliman CL, Korsmeyer SJ: Bcl-2 functions in an antioxidant pathway to prevent apoptosis. Cell 1993; 75: 241-251.
26. Kane DJ, Sarafian TA, Anton R, Hahn H, Gralla EB, Valentine JS, Ord T, Bredesen DE: Bcl-2 inhibition of neural death: decreased generation of reactive oxygen species. Science 1993; 262: 1274-1277.
27. Korsmeyer SJ, Yin XM, Oltvai ZN, Veis-Novack DJ, Linette GP: Reactive oxygen species and the regulation of cell death by the bcl-2 gene family. Biochim Biophys Acta 1995; 1271: 63-66.
28. Xu L, Chen WF, Wong MS: Ginsenoside Rg1 protects dopaminergic neurons in a rat model of Parkinson's disease through the IGF-I receptor signalling pathway. Br J Pharmacol 2009; 158: 738-748.